Ken Griffin Caribou Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,000 shares of CRBU stock, worth $42,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,000
Previous 20,500
12.2%
Holding current value
$42,300
Previous $105,000
72.38%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRBU
# of Institutions
141Shares Held
53.6MCall Options Held
37.4KPut Options Held
89.8K-
Black Rock Inc. New York, NY6.95MShares$16.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.62MShares$10.9 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.16MShares$9.78 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA4.08MShares$9.6 Million0.34% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.34MShares$5.51 Million0.01% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $143M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...